dementia glp-1 Weight-Loss Drugs May Reduce Buildup of Alzheimer's Proteins, Major Review Finds : ScienceAlert glp-1 agonist alzheimer's Potential Role

Glucagon-like peptide-1 (GLP-1) receptor agonists, a new class of drugs sold under names such as Ozempic, Wegovy, and Zepbound, are soaring in popularity for their ability to achieve and sustain substantial weight loss and improve cardiometabolic health

55689 (Dec

Physical examination, anthropometric measurements, biochemical blood analyses, and abdominal ultrasound were performed on the same day

Who responds best to CagriSema Ideal candidates: Significant obesity (BMI 30-40+) Previously plateaued on GLP-1s alone Need maximum weight loss Good GI tolerability Metabolic syndrome or diabetes Commitment to long-term use Excellent responders: Higher baseline weight (more to lose) Good adherence to protocol Combine with diet/exercise Younger patients (better metabolism) No significant medication interactions May respond less optimally: Very low starting weight (BMI 30%): Nausea (most common) Decreased appetite (intended effect) Constipation Fatigue (especially first months) Common (10-30%): Vomiting (if nausea not managed) Diarrhea (alternating with constipation) Abdominal pain/discomfort Headache Dizziness Less common ( 40 with comorbidities Insurance covers surgery Want permanent solution Don't want ongoing injections Sourcing cagrilintide and semaglutide Obtaining these peptides requires understanding current availability